Mirati’s adagrasib scores encouraging results in KRAS-mutated lung cancer
US biotech company Mirati Therapeutics announced positive Phase II results for its investigational treatment adagrasib as a treatment for KRAS-mutated lung cancer.
...
Continue Reading →
